Efferon

Efferon was founded in 2016 by Ivan Bessonov and Alexei Morozov, graduates of the Faculty of Chemistry of Moscow State University named after M.V. Lomonosov. Disposable medical products, hemosorption columns "Efferon LPS" and "Efferon CT" have permission for clinical use in Russia. These solutions are based on the original technology of producing highly effective polymer sorbents for extracorporeal blood purification.

History

2021: Attracting 200 million rubles of investment

In July 2021, Efferon announced the attraction of 200 million rubles of investments from the Fix Ventures fund. According to the results of this transaction, the developer of sorption blood purification technologies was estimated at more than 2 billion rubles.

Efferon intends to use the funds obtained to increase the production of medical products used in the integrated therapy of sepsis, septic shock and the treatment of forms of coronavirus (COVID-19) infection.

"Efferon CT" sorption column

According to Efferon CEO Alexander Volchansky, the company's focus is on exporting medical products to Latin America, the European Union, the Middle East and China.

We are glad to support the new Russian startup with a truly global product. The Efferon team has created and continues to improve solutions that are already saving and will help save the lives of many more difficult patients. We believe in Efferon's excellent prospects in the Russian and global markets, "said Dmitry Yeremeev, founder of Fix Ventures.

President Nanolek"" Vladimir Khristenko, commenting on investing in Efferon, noted that the company is developing a fully domestic product with a thorough evidence base, which is successfully used in the treatment of sepsis.  This product managed to quickly earn recognition from leading resuscitators Russia - it is used in the treatment of severe forms of COVID-19, he added. Nanolek is an Efferon partner^[1]

Notes